Clinical Trials
4 trialsNCT04739358 2023-10-18
CNS Dose Escalation/Expansion of Tepotinib in MET-driven NSCLC
Criterium, Inc.
Phase 1/2 Terminated
NCT01982955 2022-11-08
Tepotinib With Gefitinib in Participants With Locally Advanced or Metastatic NSCLC (INSIGHT)
Merck KGaA, Darmstadt, Germany
Phase 1/2 Completed
NCT01988493 2022-08-24
Efficacy, Safety, and Pharmacokinetic of MSC2156119J in Asian Participants With Hepatocellular Carcinoma
Merck KGaA, Darmstadt, Germany
Phase 1/2 Completed
NCT02115373 2022-08-24
c-Met Second-Line Hepatocellular Carcinoma
Merck KGaA, Darmstadt, Germany
Phase 1/2 Completed